Developmental Therapeutics Clinic

Associate Professor of Medicine
Division of Hematology, Oncology and Transplantation

Dr. Patel received a BS in Molecular Biology from Vanderbilt University in 1996. He then attended Kirksville College of Osteopathic Medicine, receiving a Doctor of Osteopathy degree in 2001. Dr. Patel pursued residency in Internal Medicine at McGaw Medical Center of Northwestern University followed by a clinical research fellowship at Winthrop University Hospital (Mineola, NY) from 2004-2006. In 2006 he joined the Hematology, Oncology, and Transplantation fellowship at the University of Minnesota and in July 2010 became a faculty member of the Division. Dr. Patel is a physician-scientist researching oncolytic virus for lung cancer. In 2019, Dr. Patel became the associate program director for the Hematology, Oncology, and Transplantation fellowship program. He also leads the Experimental Therapeutics Phase I clinical program at UMN.

Assistant Professor
Department of Obstetrics, Gynecology and Women's Health (OBGYN)

Dr. Teoh is a gynecologic oncologist in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology. She graduated summa cum laude from Macalester College (2000) with a Bachelor’s degree in music. She received her M.D. degree from the Medical College of Wisconsin (2004). She completed residency training in Obstetrics & Gynecology at the University of California San Francisco (2008) and then subsequently completed a subspecialty fellowship in Gynecologic Oncology at Duke University (2010). Dr. Teoh joined the Gynecologic Oncology faculty of the Department of Obstetrics, Gynecology and Women’s Health at the University of Minnesota in 2011.

Associate Professor
Division of Hematology, Oncology and Transplantation

Dr. Fujioka is a Medical Oncologist specializing in thoracic and head/neck malignancies. Her research is focused on developing food-based chemoprevention against tobacco and environmental carcinogens. Dr. Fujioka also acts as site Principal Investigator for cancer therapy clinical trials. She joined the faculty in 2011 after completing all of her training at the University of Minnesota.

Assistant Professor of Medicine
Division of Hematology, Oncology, and Transplantation

Dr. Ajay Prakash is a medical oncologist specializing in gastrointestinal malignancies. His research is focused on understanding the relationship between the tumor microenvironment, prognosis, and treatment response, with a specific focus on the role of the microbiome. A better understanding of the microbiome, the community of organisms that reside in most human tissues, may allow us to better tailor treatments and offer patient specific guidance on cancer prevention. Dr. Prakash is committed to healthcare equity and the delivery of high-quality, academic medicine to historically underserved communities.

Assistant Professor of Medicine
Division of Hematology, Oncology, and Transplantation

Dr. Heather Beckwith received her MD from the Medical College of Wisconsin (Milwaukee) in 2006. She did her residency in Internal Medicine at the University of Minnesota. During her residency she worked on research in the laboratory of Dr. Douglas Yee investigating the tyrosine kinase inhibitor properties of BMS 554417 on the insulin-like growth factor receptor using the breast cancer cell line MCF-7. Dr. Beckwith then was chosen for a fellowship in Hematology, Oncology, and Transplantation at UMN. She became an Assistant Professor of Medicine (Hematology, Oncology, and Transplantation) at UMN in 2012.

Nurse Practitioner
University of Minnesota Physicians

1. 2020IS145 An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
2. 2021IS114 A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients with Locally Advanced or Metastatic Solid Tumors
3. 2021IS173 A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants with Advanced Cancer
4. 2022IS139 A Phase 2, Open-Label Study of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer and Other Solid Tumors (TAMARACK)
5. 2022IS180 Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with ezabenlimab in patients with advanced or metastatic solid tumors
6. 2023IS006 A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants with Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
7. 2023IS074 A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer
8. 2023IS075 A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
9. 2023IS107 A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors
10. 2023IS142 A Phase 1, Open-label Study of Oral BDTX-4933 in Patients with KRAS, BRAF and Other Select RAS/MAPK Mutation Positive Neoplasms